Picture of Alligator Bioscience AB logo

ATORX Alligator Bioscience AB Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m-12.65%
3m+31.52%
6m+109.8%
1yr+112.82%
Volume Change (%)
10d/3m-55.77%
Price vs... (%)
52w High-36.1%
50d MA-9.65%
200d MA+57.36%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-1285.34%
Return on Equity-492.71%
Operating Margin-428.49%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Alligator Bioscience AB EPS forecast chart

Profile Summary

Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
September 21st, 2000
Public Since
November 23rd, 2016
No. of Employees
59
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
se flag iconOMX Nordic Exchange Stockholm
Shares in Issue
658,904,140

ATORX Share Price Performance

Latest News for ATORX

Upcoming Events for ATORX

Q1 2024 Alligator Bioscience AB Earnings Release

Alligator Bioscience AB Annual Shareholders Meeting

Q2 2024 Alligator Bioscience AB Earnings Release

Similar to ATORX

Picture of 2cureX AB logo

2cureX AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Abliva AB logo

Abliva AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Acousort AB logo

Acousort AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Active Biotech AB publ logo

Active Biotech AB publ

se flag iconOMX Nordic Exchange Stockholm

Picture of AddLife AB logo

AddLife AB

se flag iconOMX Nordic Exchange Stockholm

FAQ